Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

The demise of danuglipron means that its clinical-stage obesity pipeline is now represented by PF-07976016, another oral drug that targets GLP-1 and gastric inhibitory peptide (GIPR) and is in ...

which evaluated the co-administration of melanocortin 4 receptor or MC4R agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide or GLP-1/GIP tirzepatide arm ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

with a host of other combinations such as GLP-1/gastric inhibitory peptide (GIP), GLP-1/glucagon, and GLP-1/amylin. IQVIA also found there were 50 other mechanisms of action being evaluated in the ...

Eli Lilly then spurred it on further with tirzepatide — a GLP-1RA and gastric inhibitory polypeptide (GIP) agonist. Tirzepatide is sold under the brand names Mounjaro and Zepbound for T2D ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Dr. Bharti Shetye, also known as Dr. Abby, CEO and Physician Owner of Dr. Abby’s Weight Management Clinic, recently joined Gayle Guyardo, host of the global health and ...